Consensus Vaxart, Inc.

Stocks

VXRT

US92243A2006

Biotechnology & Medical Research

Market Closed - OTC Markets 23:47:57 04/06/2026 +04			5-day change	1st Jan Change
0.6039 ^USD	+0.63%		+33.40%	+74.34%

10-19	Vaxart, Inc. Announces Appointment of Raquel C. Bono as Director, Chair of the Stockholder Engagement Committee, and Member of the Nominating and Governance Committee and the Clinical and Regulatory Affairs Committee	CI
10-08	Vaxart, Inc. Announces Publication of Preclinical Study Results Evaluating Its Adenovirus-Based Oral Mucosal Vaccine Platform Against H5N1	CI

Evolution of the Average Target: Vaxart, Inc.

Evolution of the Average Target - Vaxart, Inc.

Evolution of the Target Price: Vaxart, Inc.

Evolution of the Target Price - Vaxart, Inc.

Changes in Analyst Recommendations: Vaxart, Inc.

e10137.ZXIWMh9HL5-Q-vsVhlltTNwY7Dbm-EINb4qnzK7zAoI.JxsnA2wvHMehg5Rg4jIbAr9WtHHelgBIPezjlpa3U88pPnVFdhZVp9KdiA~6c2f26e93012d171ea81fca1753f53c1

Analysts' recommendations: Vaxart, Inc.

27/03/25	B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating	MT
15/08/24	Oppenheimer Initiates Vaxart at Outperform With $4 Price Target	MT
14/06/24	B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating	MT
31/01/24	B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50	MT
07/08/23	Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating	MT
19/12/22	B. Riley Lowers Vaxart's PT to $1.50 From $6, Reflecting More Conservative Estimate of Ramp-up of Norovirus; Keeps Neutral Rating	MT
02/09/22	Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating	MT
19/05/22	B. Riley Trims Vaxart's Price Target to $6 from $7 to Reflect Modest Increased Long Term Cost of Capital Amid Current Macro Conditions; Keeps Neutral Rating	MT
07/03/22	B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating	MT
29/12/21	Jefferies Analyst Starts Vaxart at Buy, Adjusts Price Target to $12 From $13	MT
02/11/21	Cantor Fitzgerald Starts Vaxart at Overweight With $15 Price Target	MT
30/06/21	Vaxart : B. Riley Downgrades Vaxart to Neutral from Buy, Lowers PT to $9 from $13 on 'Underwhelming' Immunogenicity Dataset, Challenging Near-term Catalyst Setup	MT
24/06/21	Vaxart : Jefferies Initiates Coverage on Vaxart With Buy Rating, $13 Price Target	MT
11/06/21	Vaxart : Piper Sandler Starts Vaxart at Overweight With $18 Price Target	MT
04/03/21	Vaxart : B. Riley Lowers Vaxart's Price Target to $13 from $16, Keeps Buy Rating	MT
18/11/20	Vaxart : B. Riley Adjusts Vaxart PT to $16 From $22, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VAXART, INC.					+713.01%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.07%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.43%
	CELLTRION, INC.					+38.53%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	GENMAB A/S					+4.99%
	Average					+92.10%
	Weighted average by Cap.					+23.53%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

3

Last Close Price

0.4100USD

Average target price

3.333USD

Spread / Average Target

+713.01%

High Price Target

4.000USD

Spread / Highest target

+875.61%

Low Price Target

2.000USD

Spread / Lowest Target

+387.80%

Analyst Consensus Detail

Analyst consensus - Vaxart, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Vaxart, Inc.

Ratings

Trader

Investor

-

Global

-

Quality

-

ESG MSCI

-

MarketScreener Ratings - Vaxart, Inc.

Stock Market
Stocks
VXRT Stock
Consensus Vaxart, Inc.

The best tools reserved for subscribers to boost the performance of your investments!